BIO Submits Comments to FDA on Enhancing Patient Engagement Efforts
June 12, 2017
BIO submitted comments to the Food and Drug Administration (FDA) on Enhancing Patient Engagement Efforts Across the Food and Drug Administration.
BIO applauds the FDA for its commitment to integrating patient perspectives into drug development and regulatory review processes. BIO also supports FDA’s proposed Office of Patient Affairs (OPA) to provide a more transparent, accessible, and positive experience for patient communities.
BIO agrees the proposed OPA could receive inquiries about and better coordinate patient-focused activities across the Agency, as well as play a transformative role in developing a forward-looking platform enabling patients and the scientific community to more easily obtain information about patient-focused drug development activities. OPA could also serve as a valuable resource for patients, patient advocacy organizations, and the larger scientific community.
BIO says OPA should ensure timely communication and transparency with sponsors by informing them how to incorporate patient perspective data into an Investigational New Drug Application (IND) and Marketing Application. Additionally, OPA should support and coordinate with pharmaceutical sponsors seeking to include the patient voice in drug development as well as benefit-risk assessments.
BIO provides additional recommendations on OPA governance, data management systems, and other clarifications.
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
BIO submitted comments to the Food and Drug Administration (FDA) on Enhancing Patient Engagement Efforts Across the Food and Drug Administration.
BIO applauds the FDA for its commitment to integrating patient perspectives into drug development and regulatory review processes. BIO also supports FDA’s proposed Office of Patient Affairs (OPA) to provide a more transparent, accessible, and positive experience for patient communities.
BIO agrees the proposed OPA could receive inquiries about and better coordinate patient-focused activities across the Agency, as well as play a transformative role in developing a forward-looking platform enabling patients and the scientific community to more easily obtain information about patient-focused drug development activities. OPA could also serve as a valuable resource for patients, patient advocacy organizations, and the larger scientific community.
BIO says OPA should ensure timely communication and transparency with sponsors by informing them how to incorporate patient perspective data into an Investigational New Drug Application (IND) and Marketing Application. Additionally, OPA should support and coordinate with pharmaceutical sponsors seeking to include the patient voice in drug development as well as benefit-risk assessments.
BIO provides additional recommendations on OPA governance, data management systems, and other clarifications.